2 Participants Needed

Adaptive DBS for Obsessive-Compulsive Disorder

Recruiting at 2 trial locations
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Baylor College of Medicine
Must be taking: SSRIs, Antipsychotics
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This research study is for participants that have been diagnosed with intractable Obsessive -compulsive disorder (OCD). OCD is a persistent and oftentimes disabling disorder marked by unwanted and distressing thoughts (obsessions) and irresistible repetitive behaviors. OCD affects 2-3% of the US population, and is responsible for substantial functional impairment and increased risk of early death.The only established first-line treatments for OCD are cognitive-behavioral therapy (CBT) with exposure/response prevention and certain medications. About 30-40% of patients fail to respond and few experience complete symptom resolution. Up to 25% of patients have difficulty tolerating CBT and the risk of relapse after therapies remains large. For the most severe cases, neurosurgery (surgery in the brain), has long been the option of last resort.In this study the investigators want develop an adaptive Deep Brain Stimulation (aDBS) system to use in subjects with intractable (hard to control) OCD. Deep brain stimulation remains investigational for OCD patients and is not considered standard therapy. DBS involves the surgical implantation of leads and electrodes into specific areas of the brain, which are thought to influence the disease. A pack implanted in the chest, called the neurotransmitter, keeps the electrical current coursing to the brain through a wire that connects the neurotransmitter and electrodes. It is believed deep brain stimulation may restore balance to dysfunctional brain circuitry implicated in OCD. The goal of this study is to enhance current approaches to DBS targeting in the brain and to use a novel approach to find a better and more reliable system for OCD treatment.Phase Ia is to gather data to eventually develop a prototype adaptive DBS system for intractable OCD that uses signals from the brain to automatically adjust the DBS stimulation factors. The overall goal is to improve symptom management and reduce stimulation-induced behavioral side effects.

Will I have to stop taking my current medications?

The trial requires that participants have a stable psychotropic medication regimen for the month before surgery, so you may need to continue your current medications if they are stable. The protocol does not specify stopping any medications.

Is adaptive DBS safe for humans?

Deep brain stimulation (DBS) for obsessive-compulsive disorder (OCD) has been studied for safety, showing that while some serious side effects can occur, most are mild or moderate and often resolve with adjustments. In a study with 30 patients, all experienced side effects, but the majority were not severe and were related to the device's programming or stimulation.12345

How is the Adaptive DBS treatment for OCD different from other treatments?

Adaptive DBS (deep brain stimulation) for OCD is unique because it involves implanting a device that delivers electrical stimulation to specific brain areas, such as the ventral part of the anterior limb of the internal capsule, to reduce symptoms. This approach is different from traditional treatments like medication or therapy, as it directly targets brain circuits involved in OCD, offering hope for patients who do not respond to other treatments.56789

What data supports the effectiveness of the treatment Activa PC+S DBS implant for OCD?

Research shows that deep brain stimulation (DBS) can significantly reduce OCD symptoms, with some studies reporting an average improvement of 42% to 73% in symptom severity. Many patients also experience a better quality of life after DBS treatment.156710

Who Is on the Research Team?

Wayne Goodman, M.D. | BCM

Wayne K Goodman, MD

Principal Investigator

Baylor College of Medicine

Are You a Good Fit for This Trial?

This trial is for adults aged 21-70 with severe OCD that hasn't improved after trying many treatments, including cognitive-behavioral therapy and various medications. Participants must have a significant history of OCD symptoms causing distress and impairment, not be at high risk of suicide or impulsivity, and cannot have other major neurological conditions or be pregnant.

Inclusion Criteria

My OCD wasn't helped by adding antipsychotics to my treatment.
I am between 21 and 70 years old.
I have had OCD for over 5 years, and treatments haven't worked well for me.
See 11 more

Exclusion Criteria

I only have Essential Tremor and no other neurological conditions or brain injuries.
Non-Implanted Control Subject Exclusion criteria: Contraindications to MRI
I am not pregnant.
See 17 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

4 weeks
2 visits (in-person)

Treatment

Subjects undergo a single stage DBS surgery, followed by post-operative evaluations and device programming

8 weeks
Multiple visits (in-person) for surgery and follow-up

Post-surgical Monitoring

Participants return to clinic every 2 weeks for the first 2 months following system activation for assessments and recordings

8 weeks
Bi-weekly visits (in-person)

CBT Augmentation

Participants receive a two-month cognitive behavioral therapy course starting at Month 7

2 months

Double Blinded Discontinuation

One-month blinded discontinuation period to confirm clinical benefit

1 month

Monthly Programming/Classification/Evaluation

Monthly visits for programming and evaluation from Month 10 to 18

9 months
Monthly visits (in-person)

Long-Term Follow-Up

Device remains implanted for subjects doing well clinically, with follow-up management arranged on a case-by-case basis

At least 2 years

What Are the Treatments Tested in This Trial?

Interventions

  • Activa PC+S DBS implant for OCD
Trial Overview The study tests an adaptive Deep Brain Stimulation (aDBS) system in patients with hard-to-treat OCD. It involves surgically placing electrodes in the brain to regulate abnormal activity. The goal is to improve symptom management and reduce side effects by adjusting stimulation based on brain signals.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: One Month Blinded Discontinuation PeriodExperimental Treatment1 Intervention
all subjects will enter a one-month blinded discontinuation period to confirm clinical benefit at the end of Month 8.
Group II: Activa PC+S DBS implant for OCDExperimental Treatment1 Intervention
all subjects will receive surgical implantation of DBS system

Find a Clinic Near You

Who Is Running the Clinical Trial?

Baylor College of Medicine

Lead Sponsor

Trials
1,044
Recruited
6,031,000+

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Trials
1,403
Recruited
655,000+

Brown University

Collaborator

Trials
480
Recruited
724,000+

University of Pittsburgh

Collaborator

Trials
1,820
Recruited
16,360,000+

Medtronic

Industry Sponsor

Trials
627
Recruited
767,000+
Geoff Martha profile image

Geoff Martha

Medtronic

Chief Executive Officer since 2020

Finance degree from Penn State University

Dr. Richard Kuntz profile image

Dr. Richard Kuntz

Medtronic

Chief Medical Officer since 2023

MD, MSc

Carnegie Mellon University

Collaborator

Trials
80
Recruited
540,000+

Published Research Related to This Trial

In a study of 30 patients with severe, treatment-refractory OCD, deep brain stimulation (DBS) showed a 42% reduction in obsessive-compulsive symptoms after 12 months, with a responder rate of 60%.
While all patients experienced adverse events (195 total), most were mild or moderate, and the serious adverse events were primarily transient anxiety and worsening of affective symptoms, suggesting that the benefits of DBS may outweigh the risks in this challenging patient population.
A prospective international multi-center study on safety and efficacy of deep brain stimulation for resistant obsessive-compulsive disorder.Menchón, JM., Real, E., Alonso, P., et al.[2022]
Deep brain stimulation (DBS) significantly reduces symptoms of obsessive-compulsive disorder (OCD) and depression, with mean score improvements of -15.0 on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and -13.7 on the weighted depression scale at last follow-up, based on a review of 8 randomized controlled trials and 38 observational studies involving a total of 310 participants.
The study found no significant differences in efficacy between different target sites in the brain (limbic vs. non-limbic), and the overall safety profile showed a low rate of adverse events, with an average of 0.68 adverse events per treated patient.
Efficacy, Effect on Mood Symptoms, and Safety of Deep Brain Stimulation in Refractory Obsessive-Compulsive Disorder: A Systematic Review and Meta-Analysis.Martinho, FP., Duarte, GS., Couto, FSD.[2020]
Deep brain stimulation (DBS) for treatment-resistant obsessive-compulsive disorder (OCD) has been associated with various adverse events, with psychiatric issues being the most common (40%), followed by neurological problems (19%) and infections (10%).
The study highlights that while DBS may be a viable treatment option for certain patients with refractory OCD, ongoing monitoring and further research are necessary to fully understand the long-term safety and efficacy of this intervention.
Deep brain stimulation for refractory obsessive-compulsive disorder: A review and analysis of the FDA MAUDE database.Porwal, MH., Karra, H., Sharma, U., et al.[2022]

Citations

Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases. [2023]
Active stimulation site of nucleus accumbens deep brain stimulation in obsessive-compulsive disorder is localized in the ventral internal capsule. [2016]
Clinical Outcome and Mechanisms of Deep Brain Stimulation for Obsessive-Compulsive Disorder. [2020]
Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: the search for a valid target. [2023]
A prospective international multi-center study on safety and efficacy of deep brain stimulation for resistant obsessive-compulsive disorder. [2022]
Efficacy, Effect on Mood Symptoms, and Safety of Deep Brain Stimulation in Refractory Obsessive-Compulsive Disorder: A Systematic Review and Meta-Analysis. [2020]
Deep brain stimulation for refractory obsessive-compulsive disorder: A review and analysis of the FDA MAUDE database. [2022]
Current status of deep brain stimulation for obsessive-compulsive disorder: a clinical review of different targets. [2021]
Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
Integrating precision medicine in the study and clinical treatment of a severely mentally ill person. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security